The Association for Clinical Oncology (ASCO) sent a letter to members of the U.S. House of Representatives and U.S. Senate endorsing the Provider Relief Fund Improvement Act (H.R. 5963/S. 3611).
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The Association for Clinical Oncology (ASCO), along with more than 20 other stakeholder groups, sent a letter to congressional leadership urging lawmakers in both chambers to pass legislation this year to help radiation therapy clinics continue to provide potentially life-saving care to patients with cancer.
The Association for Clinical Oncology (ASCO) joined with more than 100 organizations to urge Congress to support President Biden’s reinvigorated Cancer Moonshot and to allocate funding to support the initiative.
On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.
The Association for Clinical Oncology (ASCO) is calling on Congress to continue their bipartisan support of federally funded research. Robust, sustained, and predictable funding growth for the National Institutes of Health (NIH) and the National Cancer Institute (NCI) baseline budgets are critical in advancing our nation’s work towards combating, and ultimately curing, diseases like cancer.
The Association for Clinical Oncology (ASCO) congratulates Robert M. Califf, MD, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA).
The Association for Clinical Oncology sent comments to leadership of the United States Senate Committee on Health, Education, Labor, and Pensions (HELP) regarding the Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act), which aims improve the nation’s public health and medical preparedness systems, in addition to improving the U.S. healthcare system more broadly.
The Association for Clinical Oncology (ASCO) applauds President Biden for his decision to relaunch the Cancer Moonshot with ambitious and worthy goals of reducing the death rate from cancer and improving the experience of patients and families living with cancer.
World Cancer Day, held annually on February 4, is a global initiative led by the Union for International Cancer Control (UICC). This year’s event calls on the oncology community to “close the care gap,” with a focus on recognizing and understanding the inequities in cancer care and working to address them.
On January 25, 2022, the Food and Drug Administration approved tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
The Association for Clinical Oncology (ASCO) submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Patient Protection and Affordable Care Act 2023 Notice of Benefit and Payment Parameters proposed rule.
On January 13, 2022, the U.S. Supreme Court ruled to allow the Centers for Medicare & Medicaid Services to enforce its vaccine mandate nationwide (with the exception of Texas). At the same time, the Court blocked the U.S. Occupational Safety and Health Administration from enforcing the large-employer vaccine mandate under an Emergency Temporary Standard. Physician offices are not subject to the mandate, but physicians and other providers admitting and/or treating patients in-person within a facility subject to CMS’ health and safety regulations and included in the mandate must be vaccinated so that the facility is compliant.
In many areas of the United States, the healthcare system is facing critical workforce shortages. The American Society of Clinical Oncology (ASCO) encourages public health officials and healthcare facilities to follow Centers for Disease Control and Prevention (CDC) guidelines for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-CoV-2. These guidelines allow for different levels of restrictions on staffing based on the level of shortages being experienced. However, in making these decisions, ASCO strongly encourages institutions and public health agencies to recognize the greater risk of infection and adverse outcomes that immune-suppressed individuals, including many patients with cancer, face from SARS-CoV-2 and to make decisions about staffing for the care of those individuals with thoughtful consideration of that greater risk. Unless no alternative exists, COVID-19 positive health workers, even if asymptomatic, should not be assigned to care for patients with cancer
The Centers for Medicare & Medicaid Services (CMS) released the 2023 Medicare Advantage and Part D proposed rule. The proposal aims to advance the administration’s efforts to improve consumer protections, reduce disparities, and improve health equity in Medicare Advantage (MA) and Part D.
The U.S. Department of Health and Human Services (HHS) has announced the availability of nearly $48 million in grants for community-based organizations to expand public health capacity in rural and tribal communities through health care job development, training, and placement.